Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
JAMA. 2022 Jun 7;327(21):2104-2113. doi: 10.1001/jama.2022.7993.
The efficacy and safety of prone positioning is unclear in nonintubated patients with acute hypoxemia and COVID-19.
To evaluate the efficacy and adverse events of prone positioning in nonintubated adult patients with acute hypoxemia and COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, unblinded randomized clinical trial conducted at 21 hospitals in Canada, Kuwait, Saudi Arabia, and the US. Eligible adult patients with COVID-19 were not intubated and required oxygen (≥40%) or noninvasive ventilation. A total of 400 patients were enrolled between May 19, 2020, and May 18, 2021, and final follow-up was completed in July 2021.
Patients were randomized to awake prone positioning (n = 205) or usual care without prone positioning (control; n = 195).
The primary outcome was endotracheal intubation within 30 days of randomization. The secondary outcomes included mortality at 60 days, days free from invasive mechanical ventilation or noninvasive ventilation at 30 days, days free from the intensive care unit or hospital at 60 days, adverse events, and serious adverse events.
Among the 400 patients who were randomized (mean age, 57.6 years [SD, 12.83 years]; 117 [29.3%] were women), all (100%) completed the trial. In the first 4 days after randomization, the median duration of prone positioning was 4.8 h/d (IQR, 1.8 to 8.0 h/d) in the awake prone positioning group vs 0 h/d (IQR, 0 to 0 h/d) in the control group. By day 30, 70 of 205 patients (34.1%) in the prone positioning group were intubated vs 79 of 195 patients (40.5%) in the control group (hazard ratio, 0.81 [95% CI, 0.59 to 1.12], P = .20; absolute difference, -6.37% [95% CI, -15.83% to 3.10%]). Prone positioning did not significantly reduce mortality at 60 days (hazard ratio, 0.93 [95% CI, 0.62 to 1.40], P = .54; absolute difference, -1.15% [95% CI, -9.40% to 7.10%]) and had no significant effect on days free from invasive mechanical ventilation or noninvasive ventilation at 30 days or on days free from the intensive care unit or hospital at 60 days. There were no serious adverse events in either group. In the awake prone positioning group, 21 patients (10%) experienced adverse events and the most frequently reported were musculoskeletal pain or discomfort from prone positioning (13 of 205 patients [6.34%]) and desaturation (2 of 205 patients [0.98%]). There were no reported adverse events in the control group.
In patients with acute hypoxemic respiratory failure from COVID-19, prone positioning, compared with usual care without prone positioning, did not significantly reduce endotracheal intubation at 30 days. However, the effect size for the primary study outcome was imprecise and does not exclude a clinically important benefit.
ClinicalTrials.gov Identifier: NCT04350723.
俯卧位对未插管的急性低氧血症和 COVID-19 患者的疗效和安全性尚不清楚。
评估俯卧位对未插管的成人急性低氧血症和 COVID-19 患者的疗效和不良事件。
设计、设置和参与者:在加拿大、科威特、沙特阿拉伯和美国的 21 家医院进行的实用、非盲随机临床试验。符合条件的成年 COVID-19 患者未插管,需要氧气(≥40%)或无创通气。2020 年 5 月 19 日至 2021 年 5 月 18 日期间共纳入 400 名患者,最终随访于 2021 年 7 月完成。
患者被随机分为清醒俯卧位(n=205)或不进行俯卧位的常规护理(对照组;n=195)。
主要结局为随机分组后 30 天内气管插管。次要结局包括 60 天死亡率、30 天无侵入性机械通气或无创通气天数、60 天无重症监护室或医院天数、不良事件和严重不良事件。
在 400 名随机分组的患者中(平均年龄,57.6 岁[SD,12.83 岁];117[29.3%]为女性),所有人(100%)都完成了试验。在随机分组后的前 4 天,俯卧位组的中位俯卧位时间为 4.8 小时/天(IQR,1.8 至 8.0 小时/天),对照组为 0 小时/天(IQR,0 至 0 小时/天)。到第 30 天,俯卧位组有 205 名患者(34.1%)需要插管,而对照组有 195 名患者(40.5%)需要插管(风险比,0.81[95%CI,0.59 至 1.12],P=0.20;绝对差值,-6.37%[95%CI,-15.83%至 3.10%])。俯卧位治疗并未显著降低 60 天死亡率(风险比,0.93[95%CI,0.62 至 1.40],P=0.54;绝对差值,-1.15%[95%CI,-9.40%至 7.10%]),也没有显著影响 30 天无侵入性机械通气或无创通气天数,或 60 天无重症监护室或医院天数。两组均无严重不良事件。在清醒俯卧位组中,21 名患者(10%)出现不良事件,最常见的是俯卧位引起的肌肉骨骼疼痛或不适(205 名患者中的 13 例[6.34%])和低氧血症(205 名患者中的 2 例[0.98%])。对照组无报告不良事件。
在急性低氧性呼吸衰竭的 COVID-19 患者中,与常规护理相比,俯卧位并未显著降低 30 天内气管插管的发生率。然而,主要研究结果的效应大小不够精确,不能排除临床重要的益处。
ClinicalTrials.gov 标识符:NCT04350723。